Salmon calcitonin was administered intravenously at a dose of 5 MRC units per day to a patient with prostatic cancer and bone metastases during 20 days period. Serum calcium maintained pretreatment level during the period of administration with a slight decrease after cessation of the treatment.
Urinary total hydroxyproline showed a gradual decrease during the treatment.
Serum alkaline phosphatase increased gradually, and the elevated level continued even after cessation of the administration. Urinary phosphorus increased transiently after the initiation of the administration. When hexestrol was administered intramuscularly at a total dose of 765 mg, enlarged cervical lymph nodes and metastatic lung infiltration disappeared completely at the end of the treatment.
Urinary hydroxyproline began to increase at the initiation of administration, and the high value was maintained during and after the hexestrol therapy.
It is generally accepted that calcitonin inhibits bone resorption, decreases serum calcium and antagonizes the action of parathyroid hormone on bone (Raisz et al., 1967; O'Riordan and Aurbach, 1968) . Calcitonin may, therefore, be useful in the management of patients with hypercalcemia or an enhanced resorption of bone. Effects of calcitonin have been described in hypercalcemia of various etiologies including metastatic bone disease (Bell et al., 1970; Bijvoet et al., 1968 ), Paget's disease (Bell et al., 1970) , and senile osteoporosis (Cohn et al., 1971) . Huggins (1941) had proved that estrogens were effective in preventing the progression of prostatic cancer and metastatic bone disease.
In this report the effects of salmon calcitonin (SCT) and of large dose of hexestrol were investigated in a patient with prostatic cancer and bone metastases. Fiske-SubbaRow (1925) , and urinary hydroxyproline by the method of Prockop and Udenfriend (1960 found; the cervical lymph nodes were 1.5 to 2cm in diameter and showed hard smooth surface. Thyroid gland was not palpable. Coarse rales were heard over the both lung fields, more prominently on the lower lobe. The heart was not enlarged;
there was no murmur. The edge of the liver was felt 3cm below the right costal margin, and no splenomegaly was found. There was one plus edema on the pretibial region. Neurologic examination was negative. There was a knock pain and a pain by pressure on the left upper arm and the lower lumbar region. (Fig. 1) . Throughout the period of the treatment serum calcium showed values of subnormal range with a furthermore decrease after cessation of the treatment; serum phosphorus declined to subnormal levels, and then returned to normal after calcitonin administration (Fig. 1) Difference between the mean of urinary excretion of hydroxyproline for the period before and that for the period during hexestrol therapy was significant (p>0.001).
glyceride in the post-treatment period was 183mg/dl and decreased to 86mg/dl thereafter. Urinary hydroxyproline increased prominently during and even after hexestrol administration (Table 1) .
Discussion
The Cohn et al., (1971) proved that the administration of porcine calcitonin (PCT) to patients with osteoporosis induced positive calcium balance and marked decrease in urinary hydroxyproline. Milhaud et al. (1969) , Baud et al., (1969) and Hioco et al., (1970) reported clinical improvement in osteoporotic patients treated with PCT. Calcitonin also has been shown to be therapeutically effective in treating Paget's disease (Bijvoet et al., 1968; Haddad et al., 1970) . Several workers have shown a lowering of serum calcium upon administration of calcitonin to patients with hypercalcemia which was idiopathic (Milhaud and Job, 1966) or secondary to malignancy (Bijvoet et al., 1968; Pak et al., 1968) . Pak et al., (1968) reported a case with parathyroid carcinoma and hyperparathyroidism who responded to calcitonin therapy with a fall in serum and urinary calcium, with a change in calcium balance from negative toward positive. Morii et al., (1971) proposed that calcitonin therapy was effective in lowering serum calcium in a case of hypernephroma with bone metastases. By the 14th day, urinary hydroxyproline decreased gradually after initiation of administration of calcitonin, and returned toward initial levels thereafter in the present case. Both osteoblastic and osteolytic types of bone metastases from prostatic cancer were reported. Spencer et al., (1967) known. However, the antiandrogenic action and the inhibition of gonadotropin secretion would be beneficial in suppressing tumor growth (Huggins and Hodges, 1941) . Since estrogen may also have a direct inhibitory effect on cancer cells, not only the invasion of bone by tumor cells was alleviated but also the process of bone formation may have been accelerated by estrogen. Spencer et al.,(1967) proposed alkaline phosphatase is a good prognostic indicator of the effect of estrogen therapy. A marked elevation of urinary excretion of hydroxyproline would be a reflection of the increased activity of osteoblastic process in our patient.
